Rhein Biotech's vaccines strategy

Rhein Biotech N.V. has abandoned its blue-collar roots in enabling technology to become a more up-scale vaccine products company. Rhein (NMarkt:RBO, Maastricht, the Netherlands) had been producing and outlicensing recombinant proteins until last week, when it acquired an 80 percent stake in Green Cross Vaccine Corp., a subsidiary of Korea Green Cross, in a transaction valued at $110 million.

The deal gives RBO a product pipeline worth $60 million annually and a sales gateway to the developing world (see B5). RBO now plans to develop its own vaccines pipeline and to push its new product portfolio into Europe and the U.S., as well...